ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.

NCT07390409 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

3700

Enrollment

OTHER

Sponsor class

Conditions

HIV

Interventions

DRUG: Lenacapavir Injection
DRUG: Cabotegravir (CAB) LA
DRUG: Tenofovi-Emtricitabine (TDF/FTC) tablet

Sponsor

Desmond Tutu HIV Foundation

Collaborators

[object Object]
[object Object]
[object Object]